PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Autor: | Israel Lowy, N. Alice Yama-Dang, Jingjin Li, June Y. Hou, Suk Young Yoo, Kyriakos P. Papadopoulos, Danny Rischin, Joaquina Baranda, Antonio González-Martín, M. Feng, Daniel Cho, Melissa Mathias, Silvia C. Formenti, Marta Gil-Martin, Wen Fury, Gerald Steven Falchook, Kathleen N. Moore, Salma K. Jabbour, Aung Naing, Irene Brana, Matthew G. Fury, Elizabeth Stankevich |
---|---|
Přispěvatelé: | Institut Català de la Salut, [Rischin D] Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. [Gil-Martin M] Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. [González-Martin A] Clinica Universidad de Navarra, Madrid, Spain. [Braña I] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Hou JY] Division of Gynecologic Oncology, Columbia University Medical Center, New York, NY, USA. [Cho D] Perlmutter Cancer Center at NYU Langone Medical Center, New York, NY, USA, Vall d'Hebron Barcelona Hospital Campus |
Rok vydání: | 2020 |
Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty medicine.medical_treatment Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Uterine Cervical Neoplasms Adenocarcinoma Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Female::Uterine Neoplasms::Uterine Cervical Neoplasms [DISEASES] Other subheadings::Other subheadings::/drug therapy [Other subheadings] Antibodies Monoclonal Humanized B7-H1 Antigen Coll uterí - Càncer - Tractament 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Internal medicine Biomarkers Tumor medicine Carcinoma Neoplasms::Neoplasms by Histologic Type::Neoplasms Glandular and Epithelial::Carcinoma::Carcinoma Squamous Cell [DISEASES] Humans neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma de células escamosas [ENFERMEDADES] Aged Cervical cancer Chemotherapy business.industry Obstetrics and Gynecology Histology Middle Aged medicine.disease 030104 developmental biology Tolerability 030220 oncology & carcinogenesis Cohort Carcinoma Squamous Cell Biomarker (medicine) Administration Intravenous Female business neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino [ENFERMEDADES] |
Zdroj: | Scientia |
ISSN: | 0090-8258 |
Popis: | Cemiplimab; Càncer de coll uterí metastàtic; Càncer de coll uterí recurrent Cemiplimab; Cáncer de cuello uterino metastásico; Cáncer de cuello uterino recurrente Cemiplimab; Metastatic cervical cancer; Recurrent cervical cancer Objectives To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed death-ligand 1 (PD-L1) expression. Methods In non-randomized phase I expansion cohorts, patients (squamous or non-squamous histology) received cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks, either alone (monotherapy cohort) or with hfRT during week 2 (combination cohort). Due to insufficient tissue material, PD-L1 protein expression was evaluated in commercially purchased samples and mRNA expression levels were analyzed from The Cancer Genome Atlas (TCGA). Results Twenty patients enrolled in both cohorts in total; 10 had squamous histology. The most common adverse events of any grade were diarrhea, fatigue, and hypokalemia, occurring in 35%, 25%, and 25%, respectively. Objective response rate was 10% in each cohort; responders had squamous histology. Duration of response was 11.2 months and 6.4 months for the responder in the monotherapy and combination cohort, respectively. Irradiated lesions were not included in the response assessments. In separate archived specimens ( N = 155), PD-L1 protein expression in tumor and immune cells was negative ( |
Databáze: | OpenAIRE |
Externí odkaz: |